Status:
RECRUITING
Post Marketing Study on Pluvicto in Korea
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18-100 years
Brief Summary
Post marketing study on Pluvicto in Korea
Detailed Description
This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Study participants eligible for inclusion in this study must meet all of the following criteria:
- Male adult patient age ≥ 18
- Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
- Subject who provided the written informed consent prior to the study enrollment
- Exclusion criteria
- Study participants meeting any of the following criteria are not eligible for inclusion in this study:
- Subject whose medical record is not accessible
- Subject who is not willing to provide the informed consent
Exclusion
Key Trial Info
Start Date :
April 18 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2028
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT06514521
Start Date
April 18 2025
End Date
May 31 2028
Last Update
December 30 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea, 13620
2
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea, 10408
3
Novartis Investigative Site
Seoul, Seoul, South Korea, 06351
4
Novartis Investigative Site
Seoul, South Korea, 03722